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1. Introduction 
The kynurenine pathway represents a major route for the catabolism of tryptophan (TRP). In 
the body, TRP is transported around the periphery either bound to albumin (90%) or in free 
form (10%), the two states existing in equilibrium (McMenamy 1965). However, only free form 
TRP can be transported across the blood-brain barrier (BBB) by the competitive and non-
specific L-type amino acid transporter (Hargreaves and Pardridge 1988). Once in the central 
nervous system (CNS), TRP acts as a precursor to several metabolic pathways, such as for the 
synthesis of kynurenine (KYN), serotonin, melatonin and protein (Fig. 1) (Ruddick et al. 2006). 
 
 
Fig. 1. TRP in the CNS. Only free TRP can cross the BBB and act as precursor for protein, 
serotonin, tryptamine, and kynurenine and kynuramine synthesis. The kynurenine pathway 
is a major pathway for TRP catabolism. Adapted from (Ruddick et al. 2006). 
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In the CNS, the kynurenine pathway is present to varying extents in most cell types, including 
astrocytes (Guillemin et al. 2000), neurons (Guillemin et al. 2007), infiltrating macrophages and 
microglia (Guillemin et al. 2003), oligodendrocytes (Lim et al. 2007), and endothelial cells (Owe-
Young et al. 2008). Infiltrating macrophages, activated microglia and neurons have the 
complete repertoire of kynurenine pathway enzymes. On the other hand, neuroprotective 
astrocytes and oligodendrocytes lack the enzyme, kynurenine 3-monooxygenase (KMO) and 
indoleamine 2,3-dioxygenase 1 (IDO-1) respectively, and are incapable of synthesizing the 
excitotoxin, quinolinic acid (QUIN) (Guillemin et al. 2000; Lim et al. 2007).  
The oxidation of TRP, initiating the kynurenine pathway (Fig. 2), may be catalyzed by one of 
three enzymes - TRP 2,3-dioxygenase (TDO), IDO-1 or IDO-2, a newly discovered IDO 
related enzyme (Salter and Pogson 1985; Takikawa et al. 1986; Ball et al. 2007; Metz et al. 
2007). TDO resides primarily in the liver, although it is also expressed in low quantities in 
the brain, and is induced by TRP or corticosteroids (Salter and Pogson 1985; Miller et al. 
2004). In contrast, IDO-1 is the predominant enzyme extra-hepatically and is found in 
numerous cells, including macrophages, microglia, neurons and astrocytes (Guillemin et al. 
2001; Guillemin et al. 2003; Guillemin et al. 2005; Guillemin et al. 2007). IDO-1 is up regulated 
by certain cytokines and inflammatory molecules, such as lipopolysaccharides, amyloid 
peptides and human immunodeficiency virus (HIV) proteins (Fujigaki et al. 1998; Guillemin 
et al. 2003; Takikawa 2005), and its most potent stimulant is interferon gamma (IFN-Ǆ) 
(Hayaishi and Yoshida 1978; Werner-Felmayer et al. 1989). IFN-Ǆ induces both the gene 
expression and enzymatic activity of IDO-1 (Yasui et al. 1986; Dai and Gupta 1990). IDO-2 
possesses similar structural and enzymatic activities as IDO-1. However, the two enzymes 
differ in their expression pattern and signalling pathway, and IDO-2 is preferentially 
inhibited by D-1-methyl-tryptophan (D-1-MT) (Ball et al. 2007; Metz et al. 2007). 
The first stable intermediate from the kynurenine pathway is KYN. Subsequently, several 
neuroactive intermediates are generated. They include the free-radical generator, 3-
hydroxyanthranilic acid (3HAA) (Goldstein et al. 2000), the excitotoxin and N-methyl D-
aspartate (NMDA) receptor agonist, QUIN (Stone and Perkins 1981), the NMDA antagonist, 
kynurenic acid (KYNA) (Perkins and Stone 1982), and the neuroprotectant, picolinic acid 
(PIC) (Jhamandas et al. 1990).  
The kynurenine pathway first aroused great interest when it was observed that an 
accelerated and sustained degradation of TRP occurred when activated T cells released IFN-
Ǆ during an immune response (Pfefferkorn 1984). The significance was speculated to be a 
defence mechanism that starved tumour cells, pathogens and parasites of TRP (Pfefferkorn 
1984; Brown et al. 1991). Further research soon discovered that IDO-1 activity was necessary 
for the preservation of allogeneic foetuses in mice, and that TRP depletion had an anti-
proliferative and apoptotic effect on T cells (Munn et al. 1998; Munn et al. 1999; Lee et al. 
2002). Hence, the kynurenine pathway appeared to exert an immuno-regulatory effect. In 
particular, the general control non-derepressible-2 kinase (GCN2) was identified as a key 
mediator in IDO-1 induced TRP depletion immunosuppression (Munn et al. 2005). The 
activation of GCN2 triggered a stress-response program that resulted in cell-cycle arrest, 
differentiation, adaptation or apoptosis (de Haro et al. 1996; Rao et al. 2004; Bi et al. 2005). 
Furthermore, some of the kynurenines, such as QUIN and 3HAA, can selectively target 
immune cells undergoing activation, thus suppressing T cell proliferation (Frumento et al. 
2002; Fallarino et al. 2003). They can also act in concert to produce an additive effect (Terness 
et al. 2002). Lastly, the production of the excitotoxic QUIN was often significantly increased 
following inflammation and resulting immune activation (Moffett et al. 1997).  
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Fig. 2. The kynurenine pathway. Via the kynurenine pathway, TRP is converted to 
nicotinamide adenine dinucleotide (NAD) in a series of biochemical steps. In the process, 
neuroactive intermediates are produced. The neuroprotectants include kynurenic acid and 
picolinic, and the neurotoxin, QUIN. 
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To date, the kynurenine pathway has been implicated in a wide range of diseases and disorders, 
including infectious diseases (e.g. HIV), neurological disorders (e.g. Alzheimer’s disease (AD), 
Huntington’s disease (HD) and ALS), affective disorders (e.g. schizophrenia, depression and 
anxiety), autoimmune diseases (e.g. multiple sclerosis and rheumatoid arthritis), peripheral 
conditions (e.g. cardiovascular disease) and malignancy, and a key indicator is often the up-
regulation in IDO-1 resulting in an accelerated and sustained degradation in TRP. 
2. The kynurenine pathway and QUIN in ALS 
The interest in the kynurenine pathway in the pathogenesis of ALS is relatively new. 
However, a number of studies have provided relevant results demonstrating the 
involvement of the kynurenine pathway in ALS.  
For the kynurenine pathway to be involved in the pathogenesis and progression of ALS, a 
key prerequisite has to be met – the activation of the immune response, particularly the 
presence of: (1) IFN-Ǆ, which is the most potent stimulator of IDO-1 (Takikawa et al. 1999); 
and (2) activated microglia and/or infiltrating macrophages, which are the main producers 
of QUIN in the CNS (Brew et al. 1995; Heyes et al. 1996). Figure 3 summarizes the main 
adverse events exerted by QUIN leading to motor neuron injury and death. 
A few studies have provided direct evidence between TRP metabolism and ALS. Patients 
with severe clinical status had significantly higher cerebrospinal fluid (CSF) KYNA levels 
compared to controls; however, serum KYNA levels were significantly lower in patients 
with severe clinical status compared to either controls or patients with mild clinical status 
(Ilzecka et al. 2003). This increase in CSF KYNA in patients was conjectured to be associated 
with the neuroprotective effect of KYNA, produced mainly by activated astrocytes 
(Guillemin et al. 2001).  ALS samples have also been found to have significantly higher levels 
of CSF and serum KYN and QUIN and decreased levels of serum PIC (Chen et al. 2010).   
Another study looked at Trp-32 in superoxide dismutase 1 (SOD1) protein. The aggregation 
of SOD1 is one of the hallmarks of familial ALS. Trp-32 is the only aromatic residue in SOD1 
protein and is found on the SOD1 protein surface (Zhang et al. 2003). The oxidation of Trp-
32 to KYN is responsible for bicarbonate mediated peroxidase activity induced SOD1 
aggregation (Zhang et al. 2003). By substituting Trp-32 with phenylalanine, which oxidizes 
more slowly, mutant SOD-1 motor neurons survived longer and were less likely to form 
cytoplasmic inclusions (Taylor et al. 2007). 
3. Indirect evidence for the role of QUIN in ALS 
In addition to the direct evidence demonstrating the link between the kynurenine pathway 
and ALS, numerous other studies have provided indirect evidence supporting the role of 
QUIN, in particular, in ALS. 
3.1 QUIN and SOD1 expression 
Mutations in SOD1 constitute about 20% of familial ALS cases. In rat brain, intracerebral 
injection of QUIN resulted in significant neuronal loss and a markedly increased level of 
SOD1 expression in a time-dependent manner (Noack et al. 1998). This increase in SOD1 
expression was thought to be a neuroprotective response to limit the oxidative damage 
caused by QUIN. Presumably, QUIN could have a similar effect on mutant SOD1, which 
would amplify the deleterious effects associated with mutant SOD1 pathology in ALS. 
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Fig. 3. Hypothetical model of the involvement of QUIN in the pathogenesis of ALS. QUIN, 
released from activated microglia, can induce various effects in astrocytes and motor 
neurons, including excitotoxicity, oxidative stress, apoptosis, mitochondrial dysfunction and 
the inflammatory cascade, all putatively thought to contribute to ALS disease pathogenesis 
and progression. Adapted from (Guillemin et al. 2005). 
3.2 QUIN and excitotoxicity 
QUIN is an excitotoxin and can be linked to excitotoxicity in ALS in two ways: (1) through 
the activation of the NMDA receptor; and (2) its effect on glutamate levels. The heteromeric 
NMDA receptor (NR) has three families of subunits: NR1 (A and B), NR2 (A to D) and NR3 
(A and B). In the ventral and dorsal horns of ALS spinal cord, up to 78% loss of NR2A has 
been detected (Samarasinghe et al. 1996). Interestingly, QUIN acts on the NR subtypes, 
NR1+NR2A and NR1+NR2B (Priestley et al. 1995), and the loss of NR2A in ALS patients 
may possibly reflect an excitotoxic mechanism involving QUIN. 
Glutamate induced toxicity has been implicated in the selective neuronal damage seen in 
ALS and counteracting glutamatergic toxicity, thus far, is the only treatment available for 
ALS. QUIN can potentiate its own toxicity and that of other excitatory amino acids, such as 
glutamate, under energy deprived conditions (Schurr and Rigor 1993). Moreover, QUIN 
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contributes to excessive microenvironment glutamate concentrations and neurotoxicity via 
at least three mechanisms: (1) stimulation of synaptosomal glutamate release by neurons 
(Tavares et al. 2002); (2) inhibition of glutamate uptake into synaptic vesicle by astrocytes 
(Tavares et al. 2000); and (3) limiting glutamate to glutamine recycling in astrocytes by 
decreasing glutamine synthetase activity (Baverel et al. 1990). 
3.3 QUIN and oxidative stress 
One of the putative causes of ALS is the increased production and accumulation of reactive 
oxygen species (ROS) leading to oxidative stress and lipid peroxidation. Toxicity induced by 
QUIN has been related to increase ROS and oxidative stress. Intracerebral injection of QUIN 
shows neuronal damage and increase in ROS content occurring as early as 4 hrs after 
administration (Ganzella et al. 2006).       
The lipid peroxidative effect of QUIN has also been demonstrated in vivo in adult rat brain 
(Rios and Santamaria 1991), and in rat brain synaptosomes in vitro (Santamaria et al. 2001). 
Similarly, in sheep foetal brain infused with QUIN, 4-hydroxynonenal (4-HNE), a toxic 
product of lipid peroxidation, immunoreactivity was observed in Purkinje cells and in the 
cytoplasm of cell bodies and dendrites, reaching into the molecular layer of the cerebellum 
(Yan et al. 2005). A sub-lethal dose of 4-HNE will also lead to the loss of spinal motor 
neurons in mice (Vigh et al. 2005). This may be a consequence of microglia activation, as 4-
HNE is a potent activator of microglia, which will further contribute to neuroinflammation 
and oxidative stress in ALS (Hall et al. 1998).  
In sporadic ALS patients, 4-HNE was enhanced in motor neurons and glia cells in the spinal 
cord (Shibata et al. 2001), and significantly elevated in the serum and CSF, correlating 
positively with the stage of disease (Simpson et al. 2004). CSF 4-HNE levels from sporadic ALS 
patients were also sufficient to cause the demise of motor neurons in vitro (Smith et al. 1998).   
3.4 QUIN and mitochondrial dysfunction 
Mitochondrial dysfunction is a prominent feature of ALS and predisposes motor neurons to 
ionotropic glutamate receptor-mediated excitotoxicity (Kanki et al. 2004). Excitotoxicity may 
lead to the activation of mitochondrial permeability transition pore, resulting in 
mitochondrial swelling and progressive motor neuron death (Bendotti et al. 2001). 
Intracerebral injection of QUIN, in addition to being excitotoxic, also produces progressive 
mitochondrial dysfunction leading to time-dependent energetic dysfunction, which may be 
a common and critical event in the cell death cascade seen in ALS (Bordelon et al. 1997).  
3.5 QUIN and the inflammatory cascade 
The presence of neuroinflammation is a pathological hallmark of ALS. Activated astrocytes 
and microglia are often seen in the degenerating areas surrounding injured motor neurons 
(McGeer and McGeer 2002). Elevated levels of chemokines and cytokines, such as monocyte 
chemoattractant protein 1 (MCP-1), macrophage inflammatory protein (MIP)1-, chemokine 
ligand 5, interleukin (IL)-1 to IL-12, TNF- and IFN-, have been detected in both G93A 
SOD1 mice and ALS patients (Hensley et al. 2003; Wilms et al. 2003; Henkel et al. 2004). It has 
been demonstrated that QUIN can induce astrocyte proliferation and the production of 
chemokines, particularly MCP-1 (Croitoru-Lamoury et al. 2003; Guillemin et al. 2003; Ting 
2008), and IL-1 messenger ribonucleic acid (mRNA) expression (Guillemin et al. 2003) in 
human astrocytes and macrophages. 
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3.6 QUIN and apoptosis 
In ALS, apoptosis is evident from the increased expression of pro-apoptotic proto-
oncogenes, BCl-2 and c-jun, and caspases 1 and 3 in tissue, and from the morphological 
features of apoptosis displayed by dying motor neurons. QUIN has been demonstrated to 
induce neuronal and astrocytic apoptosis involving the activation of caspase 3 (Macaya et al. 
1994; Jeon et al. 1999; Guillemin et al. 2005). Astrocytes are essential for the homeostasis of 
the CNS and so, the well-being of neurons. Hence, the loss of normal astrocytes in ALS 
would be detrimental to motor neurons and could exacerbate disease progression in ALS 
(Yamanaka et al. 2008). 
4. Potential therapeutics targeted at the kynurenine pawthay for ALS 
In 1995, riluzole became the first drug, and remains the only drug, approved by the FDA 
(USA) for treatment of ALS. The approval was based on two large placebo controlled 
clinical studies where riluzole decreased the rate of muscle deterioration and modestly 
improved the survival rate of ALS patients (Bensimon et al. 1994; Lacomblez et al. 1996). 
Though the precise mechanism of riluzole remains unclear, it appears to interfere with 
excitatory amino acid signalling, perhaps through the inhibition of glutamate release 
(Mizoule et al. 1985; Cheramy et al. 1992; Martin et al. 1993), blockade of inactivated 
sodium channels (Benoit and Escande 1991) and interaction with guanosine triphosphate 
(GTP)-binding proteins (Doble et al. 1992). 16 years on, there is still a lack of effective 
treatment available and an intense search is on going to discover better treatments for 
ALS.  
In developing therapeutic agents aimed at modulating the kynurenine pathway, two 
approaches may be taken: (1) to develop analogues of the neuroprotective kynurenines; (2) 
to inhibit the synthesis of the neurotoxic QUIN. Figure 4 summarizes the drugs targeting the 
kynurenine pathway that could be potential candidates for ALS. 
4.1 IDO inhibitors 
As the first enzyme in the kynurenine pathway, suppression of IDO would lead to 
decrease QUIN production. Although it has not been specifically tested in 
neurodegenerative disorders, it is a novel therapeutic target in cancer research and the 
results have been positive. Using transgenic mouse model of breast cancer, IDO-1 
inhibitors, 1-MT and methyl-thiohydantoin-tryptophan, were able to potentiate the 
efficacy of chemotherapy drugs, promoting tumour regression without increasing the side 
effects (Muller et al. 2005).  
4.2 4-chlorokynurenine 
QUIN neurotoxicity can be prevented by blocking the glycine modulatory site of the NMDA 
receptor (Foster et al. 1990; Hartley et al. 1990). 7-chlorokynurenate, a synthetic derivative of 
KYNA, is such an NMDA receptor antagonist (Kemp et al. 1988) but has difficulty crossing 
the BBB (Rao et al. 1993). On the other hand, its precursor, 4-chlorokynurenine, is rapidly 
transported across the BBB (Hokari et al. 1996). Intracerebral and intraperitoneal 
administration of 4-chlorokynurenine with QUIN showed successful enzymatic 
transamination of 4-chlorokynurenine into the neuroprotective 7-chlorokynurenate (Wu et 
al. 1997; Wu et al. 2000). 
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Fig. 4. Potential drug candidates targeting the kynurenine pathway for ALS. 1-MT, methyl-
thiohydantoin-tryptophan, nicotinylalanine, meta-nitrobenzoylalanine and Ro61-8048 are 
kynurenine pathway inhibitors, while 4-chlorokynurenine, laquinimod, leflunomide, 
teriflunomide and tranilast are analogues of kynurenines. 
4.3 Laquinimod 
Laquinimod (ABR-215062) is a novel synthetic quinoline with high oral bioavailability. In 
preclinical trials, the compound exhibited immunomodulatory properties without 
immunosuppression (Brunmark et al. 2002; Zou et al. 2002; Yang et al. 2004). In rats with 
experimental autoimmune encephalomyelitis (EAE), a widely used animal model for MS, 
laquinimod inhibited disease progression and infiltration of CD4+ T cells and macrophages 
into the CNS (Yang et al. 2004).  It also shifted the cytokine profile towards Th2/Th3 
cytokines IL-4, IL-10 and transforming growth factor ǃ (TGF-ǃ) (Yang et al. 2004). 
Furthermore, laquinimod is able to act synergistically with IFN-ǃ, though the mechanism of 
action is currently unknown but is independent of IFN-ǃ (Runstrom et al. 2006). In addition, 
laquinimod has also successfully reduced the development of active lesions in patients with 
relapsing MS (Polman et al. 2005).  
4.4 Leflunomide 
Leflunomide (Avara®) is an immunosuppressive and anti-inflammatory pro-drug, which is 
converted in vivo to its active open-ring metabolite, teriflunomide (A771726), an inhibitor of 
mitochondrial dihydroorotate dehydrogenase, an essential enzyme for de novo pyrimidine 
synthesis (Williamson et al. 1995).  Leflunomide is a potent inhibitor of the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) activation (Manna and Aggarwal 
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1999) and prevents Th1 cell activation while promoting Th2 cell differentiation (Dimitrova et 
al. 2002). The exact mechanism of action is still unclear though it has been shown to 
attenuate EAE independent of pyrimidine depletion (Korn et al. 2004).  
In 1998, leflunomide was approved by the FDA (USA) for the treatment of rheumatoid 
arthritis. Leflunomide has also been successful in inhibiting disease progression in 
animal models of autoimmune diseases, such as experimental autoimmune neuritis 
(Ogawa et al. 1990), EAE (Bartlett et al. 1993) and experimental myasthenia gravis (Vidic-
Dankovic et al. 1995). In a phase II trial recently, teriflunomide proved to be well 
tolerated and effective in reducing active lesions in patients with relapsing MS 
(O'Connor et al. 2006).  
4.5 Tranilast 
Tranilast (Rizaben®) is a synthetic anthranilic acid derivative drug with several inhibitory 
actions. It has the ability to inhibit the release of chemical mediators, such as histamine, 
during hypersensitivity reactions and from mast cells and also suppresses the release of 
TGF-ǃ and inhibits angiogenesis (Suzawa et al. 1992; Isaji et al. 1997). Thus, it is effective 
against many diseases, including allergic rhinitis, atopic dermatitis, bronchial asthma, 
hypertrophic scar formation and keloid. Recently, tranilast showed promising results 
against EAE, shifting the cytokine profile towards favouring Th2 cells, inhibiting the actions 
of Th1 cells and promoting the generation of IL-10 producing Th2 cells, an effect similar to 
that of natural TRP catabolites (Platten et al. 2005).  
4.6 Alanine derivatives 
The synthesis of QUIN can also be blocked by inhibiting either KYNU or KMO activity, thus 
diverting the kynurenine pathway towards the synthesis of KYNA. Nicotinylalanine is one 
such agent (Decker et al. 1963). When administered together with probenecid (to allow for 
the accumulation of KYNA by inhibiting the organic acid transport system), nicotinylalanine 
increased the amount of KYNA produced in the brain and protected the brain from induced 
seizures (Connick et al. 1992; Russi et al. 1992) and QUIN induced striatal damage (Harris et 
al. 1998). 
Another alanine derivative capable of inhibiting KMO is meta-nitrobenzoylalanine 
(Pellicciari et al. 1994). The inhibition of KMO results in an increase in brain KYN and 
KYNA, which is associated with sedation and anticonvulsant effects (Chiarugi and Moroni 
1999) and reduction in neuronal loss from brain ischemia (Cozzi et al. 1999). In immune 
activated mice, meta-nitrobenzoylalanine also significantly reduced the formation of QUIN 
in the periphery and CNS (Chiarugi and Moroni 1999). 
4.7 Ro61-8048 
Ro61-8048 (3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl] benzenesulfon-amide) is another 
potent KMO inhibitor (Rover et al. 1997). In addition to raising brain KYNA level, Ro61-8048 
also reduces glutamate concentration in the extracellular spaces of the basal ganglia in rats 
without impairing the learning or memory process typically associated with glutamate 
receptor antagonists (Moroni et al. 2005). In rats with EAE, administration of Ro61-8048 
significantly reduces the neurotoxic levels of 3-hydroxykynurenine and QUIN in the CNS 
(Chiarugi et al. 2001). Like meta-nitrobenzoylalanine, Ro61-8048 also decreases neuronal loss 
due to brain ischemia (Cozzi et al. 1999).  
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4.8 Clioquinol 
Clioquinol (5-chloro-7-iodo-8-hydroxyquinoline) is a quinoline metal chelator that binds 
selectively to zinc and copper ions (Cherny et al. 2001). Having a hydrophobic nature, it 
crosses the BBB easily. Recent research with clioquinol in neurological disorders contributed 
by an imbalance in metal ions has led to promising results, presenting the possibility of a 
new therapeutic strategy. In AD transgenic mice, treatment with clioquinol resulted in the 
dissolution of aberrant neocortex beta amyloid (Aǃ) aggregates, which are enriched with 
copper and zinc ions (Cherny et al. 2001). In a pilot phase II clinical trial, the drug was well 
tolerated and led to a significant decrease in Aǃ plasma levels in AD patients, providing 
support for future trials (Ritchie et al. 2003). In PD, elevated levels of iron in the substantia 
nigra, the brain region affected in PD, has been reported. In mice, oral administration of 
clioquinol antagonized the action of the Parkinson’s inducing agent 1-methyl-4-phenyl-
1,2,3,6-tetra-pyridine (MPTP) (Kaur et al. 2003). In HD, where iron, copper and zinc have 
been implicated, clioquinol improved the symptoms and lifespan of transgenic HD mice 
(Nguyen et al. 2005).  
A second generation 8-hydroxyquinoline, PBT2, has been developed to improve the safety 
and efficacy of clioquinol and also its pharmaceutical properties, such as solubility and 
bioavailability. In preclinical in vivo and in vitro trials on transgenic AD mice, PBT2 was 
more effective in lowering plaque formation and reducing plaque toxicity. More 
importantly, it may also improve cognition. 
5. Conclusion 
The current consensus is that ALS is a multifactorial disease. However, an explanation for 
the initiation of the putative causative mechanism of ALS remains elusive, and there lacks a 
hypothesis that can link all the mechanisms together. In recent years, the implication of the 
kynurenine pathway in multiple diseases, particularly neurodegenerative diseases, has led 
to an increase in assessing the efficacy of drugs targeting the kynurenine pathway in 
ameliorating disease symptoms and/or retarding disease progression.  
The kynurenine pathway has been demonstrated to be involved in ALS and this provides an 
important link that ties together some of the major hypotheses underlying the pathogenesis 
of ALS, namely glutamate excitotoxicity, oxidative stress, non-cell-autonomous mechanism 
and apoptosis, which are also the major mechanisms via which QUIN exerts its 
neurotoxicity effects. Due to the multiple pathways involved in the pathogenesis and 
progression of ALS, it may be speculated that a combination therapy could be more 
efficacious. Hence, by targeting the kynurenine pathway, it is hoped that more effective 
therapeutic agents, acting in synergy with other agents, may uncover a better treatment for 
ALS.  
6. Appendix 
3HAA3-hydroxyanthranilic acid 
4-HNE4-hydroxynonenal 
Aǃ Beta amyloid  
ADAlzheimer’s disease  
ALSAmyotrophic lateral sclerosis 
BBBBlood-brain barrier 
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CNSCentral nervous system 
CSFCerebrospinal fluid 
D-1-MTD-1-methyl-tryptophan 
EAEExperimental autoimmune encephalomyelitis 
GCN2General control non-derepressible-2 kinase 
GTPGuanosine triphosphate 
HDHuntington’s disease 
HIVHuman immunodeficiency virus 
IDOIndoleamine 2,3-dioxygenase  
IFN-ǄInterferon gamma 
ILInterleukin 
KMOKynurenine 3-monooxygenase 
KYNKynurenine 
KYNAKynurenic acid 
MCPMonocyte chemoattractant protein 
MIPMacrophage inflammatory protein 
MPTPMethyl-4-phenyl-1,2,3,6-tetra-pyridine 
mRNAMessenger ribonucleic acid  
NF-κBNuclear factor kappa-light-chain-enhancer of activated B cells 
NMDAN-methyl D-aspartate 
NRNMDA receptor 
PICPicolinic acid 
QUINQuinolinic acid 
ROSReactive oxygen species 
SOD1Superoxide dismutase 1 
TDOTryptophan 2,3-dioxygenase 
TGF-ǃtransforming growth factor ǃ 
TRPTryptophan 
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